Eurordis calls for change to ensure access to rare disease therapies

EURORDIS and its over 700 member patient organisations have launched a new position paper today calling for urgent change to ensure patients’ full and fast access to rare disease therapies in Europe.

The ‘Breaking the Access Deadlock to Leave No One Behind’ paper is a contribution from EURORDIS and its members and follows a reflection process initiated at the EURORDIS Symposium on Improving Patient Access to Rare Disease Therapies, held in February 2017.

It sets out a new four-pillar approach to tackling the challenges that prevent patients’ access to care and medicines, as well as the ambition to have 3 to 5 times more new rare disease therapies approved per year, 3 to 5 times cheaper than today by 2025.